ClinicalTrials.gg
CompletedNCT01553656Updated Aug 20, 2015

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

A Phase 1 interventional study of cabozantinib capsules and cabozantinib tablets in Solid Tumors, Cancer and NSCLC, sponsored by Exelixis. Completed at 2 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-08-20.

Sponsored by Exelixis · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics, pharmacogenomic (PGX) and preliminary efficacy following daily oral doses of cabozantinib (XL184) in Japanese patients with advanced or metastatic solid tumors. Also, the effect of XL184 in the treatment of non-small cell lung cancer (NSCLC) patients with various activating mutations will be evaluated at the recommended Phase 2 dose.

02

Conditions studied

  • Solid Tumors
  • Cancer
  • NSCLC

Keywords

  • Advanced cancer
  • Metastatic
  • NSCLC
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 85 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Exelixis is the lead sponsor of 57 studies on the registry; 11 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Select Inclusion Criteria:

  • Subjects with advanced or solid tumors for whom the standard of care is ineffective or inappropriate.
  • NSCLC expansion cohort subjects must have confirmed NSCLC (Stage IIIb or IV) and documented activating mutations.
  • At least 4 weeks must have elapsed from the last anti-cancer therapy. At least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin.
  • Have adequate bone marrow function, adequate liver function, and adequate renal function.
  • Sexually active subjects (men and women of (WOCBP)) must agree to use medically accepted barrier methods of (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of must agree to use both a barrier method and a second method of birth control. Women of childbearing potential (WOCBP) must have a negative pregnancy test at screening.

Select Exclusion Criteria:

  • Symptomatic central nervous system (CNS) metastasis, or active requiring medication.
  • WOCBP who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period and for 4 months after the last dose of product.
  • Women who are pregnant or breastfeeding.
  • Sexually active fertile men not using effective birth control for the entire study period and for 4 months after the last dose of investigational product if their partners are WOCBP.
  • Subjects who have uncontrolled intercurrent illness including, but not limited to, infection requiring systemic therapy, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled angina pectoris, uncontrolled peptic ulcer, cardiac arrhythmia requiring medication.
  • Subjects who are antibody positive, HBs antigen positive, and/or antibody positive.
  • Subjects with body cavity fluid retention which requires drainage.
  • Subjects with any major surgery within 8 weeks prior to study enrollment.
  • Subjects with major unhealed wounds or fracture.
  • Subjects with a history or concurrent diagnosis of gastrointestinal perforation.
  • Subjects with evidence of bleeding tendency or coagulopathy.
  • Subjects with a history of thromboembolism.
  • Subjects with a history of or concurrent pancreatitis.
  • Exposure to any investigational drug within 30 days of enrollment.
  • Subjects receiving radiation therapy or treatment with radionuclides within 6 to 2 weeks before first dose of XL184.
  • NSCLC expansion cohorts: subjects must not be diagnosed with another within 2 years before first dose of XL184.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Cabozantinib capsules and tablets

    Subjects will be enrolled in cohorts at different dose levels in order to determine the maximum tolerated dose of cabozantinib. Initially, subjects enrolled will receive the capsule formulation; other subjects will receive the tablet formulation.

    Drug: cabozantinib capsules · Drug: cabozantinib tablets

Interventions

  • cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression

    Also known as: XL184

  • cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression

    Also known as: XL184

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose

    To establish the MTD and recommended Phase 2 dose (or dose range as appropriate) of XL184 when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors.

    Time frame: Assessed in the clinic on Days 1 through 29

Secondary outcomes

  1. Safety and tolerability of XL184

    Safety and tolerability of multiple doses of XL184 administered orally on a daily basis. Assessed from informed consent until at least 30 days after discontinuation.

    Time frame: From study start to October 2014

  2. Plasma Pharmacokinetics

    Assess plasma pharmacokinetics of daily oral administration of XL184 from Treatment Day 1 to Day 29.

    Time frame: Assessed in the clinic from Day 1 through Day 29

  3. Tumor response (preliminary anti-tumor activity)

    Assess tumor response after repeated administration of XL184 from screening until discontinuation. Assessed as best overall response by cohort by radiological response defined by RECIST criteria.

    Time frame: Study start to October 2014

07

Study locations

2 sites
  • The Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR)
    Ariake, Koto 135-8550, Japan
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
08

References and documents

Publications

  • Nokihara H, Nishio M, Yamamoto N, Fujiwara Y, Horinouchi H, Kanda S, Horiike A, Ohyanagi F, Yanagitani N, Nguyen L, Yaron Y, Borgman A, Tamura T. Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2019 May;20(3):e317-e328. doi: 10.1016/j.cllc.2018.12.018. Epub 2018 Dec 31. PubMed 30718102 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of May 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2012
First posted
Mar 14, 2012
Start
Feb 2011
Primary completionActual
May 2015
CompletionActual
Jul 2015
Last update
Aug 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01553656
Lead sponsor
Exelixis
Responsible party
Sponsor
First posted
Mar 14, 2012
Start date
Feb 2011
Primary completion
May 2015
Completion
Jul 2015
Last update
Aug 20, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion